Supervivencia en cáncer de mama HER-2+ y triple negativo según el índice de carga residual tumoral post-neoadyuvancia
No hay miniatura disponible
Fecha
2022
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados
Resumen
Antecedentes: el cáncer de mama HER2 positivo y triple negativo representan los subtipos histológicos con alto riesgo de recurrencia, pero altamente sensibles a la quimioterapia, aún los pacientes con tumores pequeños pueden beneficiarse de neoadyuvancia ante la probabilidad de que células malignas hayan migrado a los ganglios y posterior a la cirugía evaluar la enfermedad residual mediante la escala del Residual Cáncer Burden o índice RCB. Objetivo: Establecer la supervivencia global (SG) según la carga residual tumoral post-neoadyuvancia en pacientes diagnosticados de cáncer de mama HER2 positivo y triple negativo. Metodología: Se realizó un estudio observacional retrospectivo, la muestra fue no probabilística, se incluyeron 33 pacientes con cáncer de mama HER2 positivo y 43 con cáncer triple negativo que hayan recibido quimioterapia neoadyuvante. Se analizó la SG a 5 años según el índice RCB en cada una de las poblaciones, las curvas de supervivencia se efectuaron por el método de Kaplan Meyer y las comparaciones mediante la prueba del Long Rank. Resultados: La probabilidad de SG a 5 años en HER2 positivo es del 100% para RCB0, 80% para RCBI, 67% para RCBII y 45% para RCBIII (p=0,201) y en cáncer de mama triple negativo del 100% para RCB0 y RCBI, del 44% para RCBII y 19% para RCBIII (p<0,001). Conclusiones: La SG a 5 años según el índice RCB tuvo una diferencia estadísticamente significativa en el grupo triple negativo pero no en el grupo HER2 positivo posiblemente por el tamaño de la muestra
Background: HER2 positive and triple negative breast cancer represent the histological subtypes with a high risk of recurrence, but highly sensitive to chemotherapy, even patients with small tumors can benefit from neoadjuvant treatment given the probability that malignant cells have migrated to the lymph nodes and later After surgery, evaluate residual disease using the Residual Cancer Burden scale or RCB index. Objective: To establish overall survival according to post-neoadjuvant residual tumor burden in patients diagnosed with HER 2 positive and triple negative breast cancer. Methodology: An observational-retrospective study was carried out, the sample was non-probabilistic, 33 patients with HER2-positive breast cancer and 43 with triple-negative cancer who had received neoadjuvant chemotherapy were included. OS at 5 years was analyzed according to the RCB index in each of the populations, survival curves were made using the Kaplan Meyer method and comparisons using the Long Rank test. Results: The probability of OS at 5 years in HER2 positive is 100% for RCB0, 80% for RCBI, 67% for RCBII and 45% for RCBIII (p=0.201) and in triple negative breast cancer it is 100% for RCB0 and RCBI , 44% for RCBII and 19% for RCBIII (p<0.001). Conclusions: The OS at 5 years according to the RCB index had a statistically significant difference in the triple negative group but not in the HER2 positive group, possibly due to the sample size.
Background: HER2 positive and triple negative breast cancer represent the histological subtypes with a high risk of recurrence, but highly sensitive to chemotherapy, even patients with small tumors can benefit from neoadjuvant treatment given the probability that malignant cells have migrated to the lymph nodes and later After surgery, evaluate residual disease using the Residual Cancer Burden scale or RCB index. Objective: To establish overall survival according to post-neoadjuvant residual tumor burden in patients diagnosed with HER 2 positive and triple negative breast cancer. Methodology: An observational-retrospective study was carried out, the sample was non-probabilistic, 33 patients with HER2-positive breast cancer and 43 with triple-negative cancer who had received neoadjuvant chemotherapy were included. OS at 5 years was analyzed according to the RCB index in each of the populations, survival curves were made using the Kaplan Meyer method and comparisons using the Long Rank test. Results: The probability of OS at 5 years in HER2 positive is 100% for RCB0, 80% for RCBI, 67% for RCBII and 45% for RCBIII (p=0.201) and in triple negative breast cancer it is 100% for RCB0 and RCBI , 44% for RCBII and 19% for RCBIII (p<0.001). Conclusions: The OS at 5 years according to the RCB index had a statistically significant difference in the triple negative group but not in the HER2 positive group, possibly due to the sample size.
Descripción
PDF
Palabras clave
Neoplasias de la mama, Factores de riesgo, Estudio retrospectivos, Supervivencia, Hospital Solca de Guayaquil, Cantón Guayaquil, Ecuador